BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28768500)

  • 1. Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
    Rolle T; Spinetta R; Nuzzi R
    BMC Ophthalmol; 2017 Aug; 17(1):136. PubMed ID: 28768500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
    Chabi A; Varma R; Tsai JC; Lupinacci R; Pigeon J; Baranak C; Noble L; Lines C; Ho TW
    Am J Ophthalmol; 2012 Jun; 153(6):1187-96. PubMed ID: 22310086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study.
    Oddone F; Tanga L; Kóthy P; Holló G;
    Adv Ther; 2020 Apr; 37(4):1436-1451. PubMed ID: 32072493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
    Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
    Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preservative-Free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% for Treatment-Naive Patients with Open-Angle Glaucoma.
    Rhee T; Kim J; Ha A
    Korean J Ophthalmol; 2024 Jun; 38(3):221-226. PubMed ID: 38665112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.
    Bourne RRA; Kaarniranta K; Lorenz K; Traverso CE; Vuorinen J; Ropo A
    BMJ Open; 2019 Apr; 9(4):e024129. PubMed ID: 30944129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
    Pfeiffer N; Traverso CE; Lorenz K; Saarela V; Liinamaa J; Uusitalo H; Astakhov Y; Boiko E; Ropo A;
    Adv Ther; 2014 Dec; 31(12):1228-46. PubMed ID: 25447269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
    Rossi GC; Blini M; Scudeller L; Ricciardelli G; Depolo L; Amisano A; Bossolesi L; Pasinetti GM; Bianchi PE
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):821-5. PubMed ID: 23944905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
    Seo du R; Ha SJ
    Biomed Res Int; 2015; 2015():435874. PubMed ID: 26557671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of country-level data from the VISIONARY study examining treatment outcomes with preservative-free tafluprost/timolol fixed-dose combination therapy.
    Holló G; Kirwan J; Lopez-Lopez F; Zimina M; Fassari C; Oddone F;
    Curr Med Res Opin; 2022 Jul; 38(7):1189-1201. PubMed ID: 35621005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.
    Aptel F; Pfeiffer N; Schmickler S; Clarke J; Lavín-Dapena C; Moreno-Montañés J; Żarnowski T; Csutak A; Jugaste T; Volksone L; Astakhov YS; Coupier L; Nordmann JP; Stalmans I;
    J Glaucoma; 2019 Jun; 28(6):498-506. PubMed ID: 31166287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications.
    Lazreg S; Merad Z; Nouri MT; Garout R; Derdour A; Ghroud N; Kherroubi R; Meziane M; Belkacem S; Ouhadj O; Baudouin C; Tiar M
    J Fr Ophtalmol; 2018 Dec; 41(10):945-954. PubMed ID: 30477719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reviewing the evidence surrounding preservative-free tafluprost/timolol fixed-dose combination therapy in open-angle glaucoma and ocular hypertension management: a focus on efficacy, safety, and tolerability.
    Oddone F
    Expert Opin Drug Saf; 2022 Oct; 21(10):1259-1268. PubMed ID: 36250245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo confocal microscopy of conjunctiva in preservative-free timolol 0.1% gel formulation therapy for glaucoma.
    Frezzotti P; Fogagnolo P; Haka G; Motolese I; Iester M; Bagaglia SA; Mittica P; Menicacci C; Rossetti L; Motolese E
    Acta Ophthalmol; 2014 Mar; 92(2):e133-40. PubMed ID: 24020826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain.
    Garcia-Medina JJ; Benitez-Del-Castillo J; Rodríguez-Agirretxe I; Lopez-Lopez F; Moreno-Valladares A;
    J Ocul Pharmacol Ther; 2022 Apr; 38(3):252-260. PubMed ID: 35230148
    [No Abstract]   [Full Text] [Related]  

  • 18. Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
    Hoy SM
    Drugs; 2015 Oct; 75(15):1807-13. PubMed ID: 26431840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance.
    Rolle T; Curto D; Alovisi C; Franzone M; Brogliatti B; Grignolo FM
    Eur J Ophthalmol; 2012; 22(1):28-33. PubMed ID: 22167540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.